Protagenic Therapeutics Reports Increased Losses and Significant Asset Growth in Latest 10-Q Filing

Protagenic Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $869,496 for the quarter, compared to a loss of $582,387 in the same period last year. For the six months ending September 30, 2025, the net loss was $5,927,019, a substantial increase from $906,742 in the prior year. The increase in losses is attributed to heightened research and development expenses, which surged to $667,341 from $36,099, alongside increased general and administrative costs and transaction fees related to the recent merger with Phytanix Bio.

The company’s total assets rose dramatically to $5,002,847 as of September 30, 2025, up from $89,093 at the end of the previous fiscal period. This increase is primarily due to the acquisition of intangible assets and cash raised through financing activities. Current liabilities also increased significantly, reaching $9,703,412, compared to $5,042,052 in March 2025, largely due to an increase in notes payable and derivative liabilities. The accumulated deficit now stands at $11,324,625, reflecting ongoing operational losses.

Strategically, Protagenic completed a reverse merger with Phytanix Bio on May 15, 2025, which has expanded its product pipeline into multiple therapeutic areas, including neurology and psychiatry. The merger included the acquisition of five preclinical drug candidates, which are expected to enhance the company’s research capabilities and market potential. The company has also initiated a restructuring plan aimed at transitioning to a virtual operating model, which is expected to reduce annual operating expenses by approximately $8 million.

Operationally, Protagenic has made significant changes to its workforce, reducing headcount primarily associated with preclinical activities. As of September 30, 2025, the company had four part-time employees and one full-time employee, alongside several paid consultants. The restructuring plan is designed to focus resources on the most promising clinical programs, particularly the ongoing Phase 2 clinical trial of its lead drug candidate, PT00114, which is anticipated to complete in approximately 9 to 12 months.

Looking ahead, Protagenic anticipates continued losses as it progresses through clinical trials and seeks regulatory approvals for its product candidates. The company has indicated that it will need to secure additional financing to sustain operations beyond its current cash reserves, which stood at $2,722,451 as of the end of September 2025. The management has expressed concerns regarding the company's ability to continue as a going concern if sufficient capital is not raised in the near future.